Management of hepatitis B: 2000--summary of a workshop.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Gastroenterology

• Publication date

  2001-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/GAST.2001.24839PMID 11375963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

  2008cited by this paper
• Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha.

  2008cited by this paper
• Relative incidence of primary liver cancer in cirrhosis in Austria. Etiological considerations.

  2008cited by this paper
• Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions

  2004cited by this paper
• Hepatitis B e‐antigen negative chronic hepatitis B

  2002cited by this paper
• Antiviral activity of clevudine [L‐FMAU, (1‐(2‐fluoro‐5‐methyl‐β, L‐arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)

  2001cited by this paper
• Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection

  2001cited by this paper
• Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays.

  2000cited by this paper
• Combination chemotherapy for hepatitis B virus: The final solution?

  2000cited by this paper
• A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B

  2000cited by this paper
• LAMIVUDINE WITHOUT HBIg FOR PREVENTION OF GRAFT REINFECTION BY HEPATITIS B: LONG-TERM FOLLOW-UP

  2000cited by this paper
• In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir

  2000cited by this paper
• Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study

  2000cited by this paper
• Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo

  2000cited by this paper
• Combination therapy with lamivudine and famciclovir for chronic hepatitis B–infected Chinese patients: A viral dynamics study

  2000cited by this paper
• Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.

  2000cited by this paper
• Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

  2000cited by this paper
• Use of CpG DNA for enhancing specific immune responses.

  2000cited by this paper
• Response of pre‐core mutant chronic hepatitis B infection to lamivudine

  2000cited by this paper
• Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

  2000cited by this paper
• Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB)

  2000cited by this paper
• Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy

  2000cited by this paper
• Hepatitis B immune globulin: the US experience.

  2000cited by this paper
• Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

  2000cited by this paper
• Low Dynamic State of Viral Competition in a Chronic Avian Hepadnavirus Infection

  2000cited by this paper
• Risk factors for the rising rates of primary liver cancer in the United States.

  2000cited by this paper
• Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

  2000cited by this paper
• Long term effect of alpha interferon in children with chronic hepatitis B

  2000cited by this paper
• A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.

  2000cited by this paper
• Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B

  2000cited by this paper
• Pathologic features of chronic hepatitis. A review and update.

  2000cited by this paper
• A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.

  2000cited by this paper
• Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants

  2000cited by this paper
• Effect of Oral Administration of Emtricitabine on Woodchuck Hepatitis Virus Replication in Chronically Infected Woodchucks

  2000cited by this paper
• Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood.

  2000cited by this paper
• Antiviral chemotherapy for the treatment of hepatitis B virus infections.

  2000cited by this paper
• An efficacy and cost‐effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

  2000cited by this paper
• Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  2000cited by this paper
• Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

  2000cited by this paper
• Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.

  2000cited by this paper
• Reversion from precore/core promoter mutants to wild‐type hepatitis B virus during the course of lamivudine therapy

  2000cited by this paper
• Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus.

  2000cited by this paper
• Long‐term therapy of chronic hepatitis B with lamivudine

  2000cited by this paper
• Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms

  2000cited by this paper
• Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B

  2000cited by this paper
• A Multicenter Study Evaluation of the Digene Hybrid Capture II Signal Amplification Technique for Detection of Hepatitis B Virus DNA in Serum Samples and Testing of EUROHEP Standards

  2000cited by this paper
• Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.

  2000cited by this paper
• Combination low‐dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B

  2000cited by this paper
• Update on prevention and treatment of viral hepatitis in children.

  1999cited by this paper
• The long‐term course of chronic hepatitis B

  1999cited by this paper
• Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks

  1999cited by this paper
• Rising Incidence of Hepatocellular Carcinoma in the United States

  1999cited by this paper
• A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus

  1999cited by this paper
• Combinatorial Screening and Intracellular Antiviral Activity of Hairpin Ribozymes Directed against Hepatitis B Virus

  1999cited by this paper
• Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

  1999cited by this paper
• Multicenter study of lamivudine therapy for hepatitis B after liver transplantation

  1999cited by this paper
• Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board.

  1999cited by this paper
• Lamivudine as initial treatment for chronic hepatitis B in the United States.

  1999cited by this paper
• Hepatocyte-directed Gene Delivery by Receptor-mediated Endocytosis

  1999cited by this paper
• Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

  1999cited by this paper
• The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination.

  1999cited by this paper
• Quantitative Detection of Hepatitis B Virus DNA in Two International Reference Plasma Preparations

  1999cited by this paper
• Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.

  1999cited by this paper
• Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.

  1999cited by this paper
• A placebo‐controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

  1999cited by this paper
• Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men

  1999cited by this paper
• Rising incidence of hepatocellular carcinoma in the United States.

  1999cited by this paper
• Carboxypeptidase D Is an Avian Hepatitis B Virus Receptor

  1999cited by this paper
• Chronic liver disease in central harlem: The role of alcohol and viral hepatitis

  1999cited by this paper
• Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.

  1999cited by this paper
• Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B

  1999cited by this paper
• Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion

  1999cited by this paper
• Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

  1999cited by this paper
• Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.

  1999cited by this paper
• Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

  1999cited by this paper
• Viral clearance without destruction of infected cells during acute HBV infection.

  1999cited by this paper
• Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.

  1999cited by this paper
• Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

  1999cited by this paper
• Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy

  1999cited by this paper
• Hepatitis B vaccination in high-risk infants: 10-year follow-up.

  1999cited by this paper
• Thymosin α1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double‐blind and placebo‐controlled study

  1999cited by this paper
• Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens.

  1999cited by this paper
• Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients

  1999cited by this paper
• Hepatitis B surface antigenemia at birth: a long-term follow-up study.

  1998cited by this paper
• Hepatocellular carcinoma

  1998cited by this paper
• Multi‐measurement method comparison of three commercial hepatitis B virus DNA quantification assays

  1998cited by this paper
• Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

  1998cited by this paper
• Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period.

  1998cited by this paper
• Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.

  1998cited by this paper
• Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.

  1998cited by this paper
• Progress toward elimination of hepatitis B virus transmission in the United States.

  1998cited by this paper
• Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

  1998cited by this paper
• Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.

  1998cited by this paper
• The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

  1998cited by this paper
• Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.

  1998cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• Hepatitis B vaccination of adolescent and adult high-risk groups in the United States.

  1998cited by this paper
• Treatment of Chronic Viral Hepatitis

  1998cited by this paper
• Lamivudine therapy of WHV-infected woodchucks.

  1998cited by this paper
• Effect of interferon- on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study

  1998cited by this paper

• Impact of TNF-α (− 308G>A and − 857 C>T) promoter variants on susceptibility to chronic hepatitis B virus infection in a cohort of Mauritanian patients: pilot study

  2026cites this paper
• Validation of quantitative hepatitis B virus DNA and hepatitis B e antigen titers in patients of chronic hepatitis B virus infection on entecavir therapy at tertiary care hospital

  2025cites this paper
• Chronic hepatitis B: Is it time for expanded antiviral treatment?

  2025cites this paper
• Complex dynamics in a delayed diffusive cell population model of hepatitis b with capsids, mitotic transmission, and non-cytopathic antiviral mechanisms

  2025cites this paper
• Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.

  2025cites this paper
• Are nucleot(s)ide analogues a negative factor for HBsAg seroconversion in acute hepatitis B?

  2024cites this paper
• The effect of Oenothera biennis (Evening primrose) oil on inflammatory diseases: a systematic review of clinical trials

  2024cites this paper
• Foxa deficiency restricts hepatitis B virus biosynthesis through epigenic silencing

  2024cites this paper
• Evaluating the impact of COVID-19 outbreak on hepatitis B and forecasting the epidemiological trend in mainland China: a causal analysis

  2024cites this paper
• Functional probes for the diagnosis and treatment of infectious diseases

  2024cites this paper
• Modelling the dynamics of acute and chronic hepatitis B with optimal control

  2023cites this paper
• Current Challenges and Future Perspectives of Diagnosis of Hepatitis B Virus

  2023cites this paper
• Injectable controlled-release systems for the prevention and treatment of infectious diseases.

  2023cites this paper
• Antiviral activity of zinc against hepatitis viruses: current status and future prospects

  2023influential citation
• Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat?

  2023cites this paper
• Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection

  2022cites this paper
• Child-Pugh Score of Decompensated Chronic Liver Disease Patient as a Predictor of Short-Term Prognosis

  2022cites this paper
• Hepatoprotective potential of selected medicinally important herbs: evidence from ethnomedicinal, toxicological and pharmacological evaluations

  2022cites this paper
• An Insight into the Hepatoprotective Activity and Structure-activity Relationships of Flavonoids.

  2022cites this paper
• Modeling of Hepatitis B Virus Transmission with Fractional Analysis

  2022cites this paper
• A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients

  2022cites this paper
• [Natural history and disease progression of chronic hepatitis B virus infection].

  2022cites this paper
• The analysis of hepatitis B virus (HBV) transmission using an epidemic model

  2021cites this paper
• Acute and Chronic Hepatitis

  2021cites this paper
• Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia.

  2021cites this paper
• Global prevalence of hepatitis B virus serological markers among healthcare workers: A systematic review and meta-analysis

  2021cites this paper
• Global Stability Analysis of HBV Epidemics with Vital Dynamics

  2021cites this paper
• A Clinical Audit Report on Compliance to Hepatitis B Vaccination in Type 2 Diabetes Mellitus Patients in a Primary Health Care Centre in Qatar

  2021cites this paper
• The Transmission Dynamics of Hepatitis B Virus via the Fractional-Order Epidemiological Model

  2021cites this paper
• Analysis of epidemiological serosurvey of hepatitis B virus among people under 29 years of age in Jiangsu Province, China

  2021cites this paper
• HEPATITIS B VIRUS AND ITS GENOTYPES CIRCULATING IN INDIA

  2021cites this paper
• Strong association of functional polymorphism in IL‐12B with susceptibility to chronic hepatitis B in Tunisia

  2021cites this paper
• Modeling and sensitivity analysis of HBV epidemic model with convex incidence rate

  2021cites this paper
• OPTIMAL CONTROL ANALYSIS OF THE EFFECT OF TREATMENT, ISOLATION AND VACCINATION ON HEPATITIS B VIRUS

  2020cites this paper
• A theoretical model of chronic hepatitis B virus with suboptimal adherence and drug resistance

  2020cites this paper
• Global dynamics of a model of hepatitis B virus infection in a sub-Saharan African rural area

  2020cites this paper
• Clinical Implications of the Molecular Biology of Hepatitis B Virus

  2020cites this paper
• Evaluating some biochemical parameters and their correlation withviral load in patients with Hepatitis B virus, Thi-Qar, Iraq

  2020cites this paper
• Mucosal‐Associated Invariant T Cell Dysregulation Correlates With Conjugated Bilirubin Level in Chronic HBV Infection

  2020cites this paper
• Determinants of Progression Rate of Hepatitis B Virus in the Liver of Patients: A Prospective Longitudinal Study

  2020cites this paper
• Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis

  2020cites this paper
• Interleukin IL‐1B gene polymorphism in Tunisian patients with chronic hepatitis B infection: Association with replication levels

  2020cites this paper
• Association of hepatocellular carcinoma risk with polymorphisms in tumour necrosis factor alpha gene in a Chinese Han population

  2020cites this paper
• Viral dynamics and control of hepatitis B virus (HBV) using an epidemic model

  2020cites this paper
• Surveillance of hepatocellular carcinoma by medical imaging.

  2019cites this paper
• Modeling and qualitative analysis of a hepatitis B epidemic model.

  2019cites this paper
• The roles of miRNAs in liver diseases

  2019cites this paper
• Optimal control of the mathematical viral dynamic model of different hepatitis B infected individuals with numerical simulation

  2019cites this paper
• [Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach].

  2019cites this paper
• Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen‐negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels

  2019cites this paper
• Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

  2018cites this paper
• HBV Facilitated Hepatocellular Carcinoma Cells Proliferation by Up-Regulating Angiogenin Expression Through IL-6

  2018cites this paper
• Long‐term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e‐antigen seroclearance

  2018cites this paper
• Study of Genotypic Variants of Hepatitis B Virus , Their Viral Load and Correlation with Alanine Aminotransferase Levels in HBsAg Positive Patients

  2018cites this paper
• The effects of booster vaccination of hepatitis B vaccine on children 5–15 years after primary immunization: A 5-year follow-up study

  2018cites this paper
• Spontaneous hepatitis B surface antigen seroconversion after long lasting hepatitis B virus infection in a chronic hemodialysis patient

  2018cites this paper
• CO-RRELATATION OF ALT & AST LEVELS WITH HEPATITIS B VIRUS DNA VIRAL LOAD

  2018cites this paper
• The expression of CD74 and macrophage migration inhibitory factor protein is upregulated in hepatitis B virus-related hepatocellular carcinoma

  2018cites this paper
• Autoimmune Kidney Diseases Associated with Chronic Viral Infections.

  2018cites this paper
• Hepatitis B Virus X Protein Increases 8-Oxo-7,8-Dihydro-2ʹ-Deoxyguanosine (8-Oxodg) Level via Repressing MTH1/ MTH2 Expression in Hepatocytes

  2018cites this paper
• Natural History of Hepatitis B Virus

  2018cites this paper
• Diagnostic value of HBsAg in HBV Infection among patients referred to Pathologist Lancet Laboratory in Nairobi, Kenya

  2018cites this paper
• 213 – Hepatitis B and Hepatitis D Viruses

  2018cites this paper
• Associations of human leukocyte antigen and interleukin-18 gene polymorphisms with viral load in patients with hepatitis B infection

  2018cites this paper
• The transmission dynamic of different hepatitis B-infected individuals with the effect of hospitalization

  2018cites this paper
• Detection of Hepatitis B Genotypes in HBsAg & HBeAg Carriers

  2018cites this paper
• Effects of curcumin on NF‐κB, AP‐1, and Wnt/β‐catenin signaling pathway in hepatitis B virus infection

  2018cites this paper
• Etiology and Pathogenesis of Hepatocellular Carcinoma

  2018cites this paper
• Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src/PI3K/Akt pathway

  2018cites this paper
• A critical review on hepatoprotective effects of bioactive food components

  2018cites this paper
• Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

  2018cites this paper
• Prevalence and Identification of Serum Markers Associated with Vertical Transmission of Hepatitis B in Pregnant Women in Yaounde, Cameroon

  2017cites this paper
• Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects

  2017cites this paper
• Kap Study of Hepatitis B and C among the Patients Attending the O.P.D of Nishtar Hospital, Multan-Pakistan

  2017cites this paper
• Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.

  2017cites this paper
• Identification of hepatitis B virus A1762T/G1764A double mutant strain in patients in Southern Brazil

  2017cites this paper
• Drugs in Development for Hepatitis B

  2017cites this paper
• Hepatic deficiency of the pioneer transcription factor FoxA restricts hepatitis B virus biosynthesis by the developmental regulation of viral DNA methylation

  2017cites this paper
• The transmission dynamic and optimal control of acute and chronic hepatitis B

  2017cites this paper
• Seroprevalence Study of Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus in Humans and Risk Factors in Suleja, Nigeria

  2017cites this paper
• Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases

  2017cites this paper
• Novel HBV mutations and their value in predicting efficacy of conventional interferon.

  2017cites this paper
• An Intracellular Differential Equation Model For The Dynamics Of Hepatitis B Virus (Hbv) Infection With Immune Control

  2017cites this paper
• Classification and sensitivity analysis of the transmission dynamic of hepatitis B

  2017cites this paper
• IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon‐&agr;2 against the hepatitis B virus through altering its binding to the receptor

  2017cites this paper
• Cross Sectional Study Regarding Knowledge Attitude and Practices of patients and their Attendants Regarding Hepatitis-B and Hepatitis-C

  2017cites this paper
• ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL

  2016cites this paper
• Comparative study on Prevalence of Hepatitis B surface antigen among blood donors and In patient hospital attendees at a tertiary care hospital , Hyderabad

  2016cites this paper
• PROBLEMAS DURANTE EL PERÍODO PERIOPERATORIO DEL TRASLANTE HEPÁTICO: PROFILAXIS Y TRATAMIENTO

  2016cites this paper
• Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006–2013

  2016cites this paper
• Global Epidemiology of Hepatitis B Virus Infection

  2016cites this paper
• α-Mannosidase I Protein Expression in Peripheral Blood Mononuclear Cells Is Upregulated During Hepatitis B Virus Infection

  2016cites this paper
• Hepatocellular carcinoma: a review

  2016cites this paper
• Exposition of hepatitis B surface antigen (HBsAg) on the surface of HEK293T cell and evaluation of its expression

  2016cites this paper
• Classification of different Hepatitis B infected individuals with saturated incidence rate

  2016cites this paper
• Hepatitis B and C Viruses

  2016cites this paper
• THE RELATIONSHIP BETWEEN SERUM DNA LEVELS AND SEROLOGICAL MARKERS , ALT AND AST WITH LIVER HISTOLOGY IN CHRONIC HEPATITIS B PATIENTS

  2016cites this paper
• Interferon Treatment for Hepatitis B.

  2016cites this paper
• Assessemnt of Biochemical, Serological, Molecular Viral Chronic Hepatitis B to Determine Therapy Response

  2016cites this paper
• KASL clinical practice guidelines: management of chronic hepatitis B

  2016cites this paper